Evidence map›Paper›PMID 40064359›Full record

ArticlePharmacological research2025

CB

Joshua Watkins, Petra Aradi, Rachel Hahn, Alexandros Makriyannis, Ken Mackie, Istvan Katona, Andrea G Hohmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Dual-target mu opioid-dopamine DEuropean journal of medicinal chemistry · 2026
    Article
  2. Cannabinoid CBBritish journal of pharmacology · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

  • Update of
    CB2024
5 · Who and what money

Authors and funding

7 authors.

Joshua WatkinsDepartment of Psychological and Brain Sciences, Indiana University Bloomington, Bloomington, IN 47405, United States; Program in Neuroscience, Indiana University Bloomington, Bloomington, IN 47405, United States.
Petra AradiDepartment of Psychological and Brain Sciences, Indiana University Bloomington, Bloomington, IN 47405, United States.
Rachel HahnDepartment of Psychological and Brain Sciences, Indiana University Bloomington, Bloomington, IN 47405, United States.
Alexandros MakriyannisCenter for Drug Discovery, Northeastern University, Boston, MA 02115, United States.
Ken MackieDepartment of Psychological and Brain Sciences, Indiana University Bloomington, Bloomington, IN 47405, United States; Program in Neuroscience, Indiana University Bloomington, Bloomington, IN 47405, United States; Gill Institute for Neuroscience, Indiana University, Bloomington, IN 47405, United States.
Istvan KatonaDepartment of Psychological and Brain Sciences, Indiana University Bloomington, Bloomington, IN 47405, United States; Program in Neuroscience, Indiana University Bloomington, Bloomington, IN 47405, United States; Institute of Experimental Medicine, HUN-REN, Budapest, Hungary.
Andrea G HohmannDepartment of Psychological and Brain Sciences, Indiana University Bloomington, Bloomington, IN 47405, United States; Program in Neuroscience, Indiana University Bloomington, Bloomington, IN 47405, United States; Gill Institute for Neuroscience, Indiana University, Bloomington, IN 47405, United States. Electronic address: hohmanna@iu.edu.

Funding

Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI Alexandros Makriyannis · 1994 to 2026
$26.0M
Multi-Scale Imaging Core (MSIC)P30DA056410 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI Kenneth Mackie · 2023 to 2026
$7.1M
INTEGRATIVE PREDOCTORAL TRAINING IN DRUG ABUSE RESEARCH AT INDIANA UNIVERSITYT32DA024628 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI Andrea Grace Hohmann, Kenneth Mackie · 2008 to 2026
$3.1M
CB2 Cannabinoid Mechanisms for Suppressing Opioid Tolerance and DependenceR01DA047858 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI HOHMANN, ANDREA GRACE, MACKIE, KENNETH · 2019 to 2023
$2.6M
NCATS NIH HHS UL1 TR002529NIDA NIH HHS P01 DA009158NIDA NIH HHS P30 DA056410NIDA NIH HHS R01 DA047858NIDA NIH HHS T32 DA024628
6 · The paper itself

Abstract

Recreational use of synthetic cannabinoid agonists (i.e., "spice compounds") that target the cannabinoid type 1 receptor (CB

Indexed as

Cannabinoid Receptor AgonistsCyclohexanolsDronabinolReceptor, Cannabinoid, CB1Respiratory InsufficiencyAnimalsFemaleMaleMiceMice, Inbred C57BLReceptors, Opioid, muRespirationWakefulness3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanolCannabinoid Receptor AgonistsCyclohexanolsDronabinolReceptor, Cannabinoid, CB1Receptors, Opioid, muCannabinoidOpioidOverdosePre-Botzinger complexRespiratory depressionTHC

Identifiers

PMID40064359
PMCPMC12057448

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.